A biopharmaceutical research and development company engaged in developing human therapeutic products based primarily upon its small molecule molecular chaperone co-induction technology.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
This stock may be near-term overpriced, but I believe its technology will lead to outsized returns over the long run, with intermittent large spikes in the stock price (upward as well as downward, but overall up). I am holding a small position from several weeks ago, from about 4.95. I will add to my position eventually.
I fully agree with you.. this stock has a lot of upside.... I think when they get their first FDA drug approval, they will sky rocket up to $20 or better.